Table 5

Efficacy of atypical antipsychotics in elderly patients with dementia: Number needed to treat
Study Study Design Follow-up Risperidone n/N (%) Placebo n/N (%) RD NNT
Clinical End Point
>50% Improvement in Behave-AD1total score
Katz [62] Double-blind placebo controlled RCT (n=625) 12 weeks (45%) (33%) 12% 8
Schneider [6] Meta Analysis of 3 studies (n=1001) 12 weeks 266/574 (46%) 139/427 (33%) 14% 7.4
>30% Improvement in Behave-AD1total score
DeDeyn [8] Double-blind placebo controlled RCT (n=344) 12 weeks (72%) (61%) 11% 9
CGI-C2 (much/very much improved)
Brodaty [61] Double-blind placebo controlled RCT (n=93) 12 weeks 27/46 (59%) 12/47 (26%) 33% 3.3
Schneider [6] Meta Analysis of 2 studies (n=717) 8-12 weeks 227/351 (65%) 175/366 (48%) 17% 6
Katz [5] Meta Analysis of 4 studies (n=889) End point (28%) (17%) 11% 9
Sultzer [63] Double-blind placebo controlled RCT (n=421) 12 weeks (61%) (40%) 21% 5

1 BEHAVE-AD: Behaviour Pathology in Alzheimer’s Disease Rating Scale.

2 CGI-C: Clinical Global Impression of Change.

Pratt et al.

Pratt et al. BMC Medical Research Methodology 2012 12:72   doi:10.1186/1471-2288-12-72

Open Data